WT1 and acute myeloid leukemia: Some studies demonstrated that the aberrant persistence of WT1 overexpression after induction chemotherapy and during the subsequent courses is associated with an increased risk of relapse, making it a significant marker for disease monitoring and risk stratification in AML patients for therapeutic response [5,6,7,8,9].